Cytori Therapeutics, Inc., a cell therapy company in San Diego, signed a three-year distribution agreement with Worthington Biochemical Corp. to place the Celase GMP enzyme in research markets in the U.S. and select locations internationally, according to a news release.

The agreement is nonexclusive and would facilitate research in regenerative medicine using Cytori’s Celase GMP to broaden the clinical applications of Cytori cell therapy and add the product to Worthington’s Collagenase and STEMxyme portfolio.

Celase GMP is an enzyme containing a blend of particular enzymes, collagenase and neutral protease, and buffer salts for in vitro dissociation of adipose tissue, or the separation of fatty tissue. Cytori develops cell therapies from tissue to treat a variety of medical conditions. According to the news release, data suggests that Cytori’s cell therapy can improve blood flow, modulate the immune system and facilitate wound repair.

Worthington Bichochemical Corp., a privately-owned manufacturer of enzymes, proteins, nucleic acids and kits for biotech and life science research, was founded in 1947 and maintains a certified facility in Lakewood, N.J.